Please use this identifier to cite or link to this item:
Title: Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?
Austin Authors: Forbes, Josephine M
Affiliation: Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Mater Research Institute, The University of Queensland, TRI, Brisbane, Queensland, Australia
Faculty of Medicine, The University of Queensland, St Lucia, Queensland, Australia
Issue Date: May-2020
Publication information: Kidney International 2020; 97(5): 855-857
Abstract: Diabetes affects oxygen availability in the kidney, forcing the renal environment to rapidly and sustainably adapt. Physiological adaptations including activation of hypoxia inducible factor-1α and metabolic reprogramming toward pathways requiring less oxygen to maintain adenosine triphosphate production such as anaerobic glycolysis are impaired in the diabetic kidney. However, this study by Hasegawa et al. demonstrates renoprotection in diabetic kidney disease via the use of the hypoxia inducible factor-1α stabilizer enarodustat, opening a new therapeutic avenue to tackle these metabolic abnormalities.
DOI: 10.1016/j.kint.2020.01.038
ORCID: 0000-0002-5595-8174
PubMed URL: 32331596
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.